



**Canadian Cardiovascular Society/Canadian Heart Rhythm Society Joint Position Statement on the Cardiovascular Screening of Competitive Athletes**

Panel Member's Relationships with Industry (RWI)

The CCS is committed to preserving the scientific integrity of its Guidelines and Position Statements through transparency and management of relationships with industry (RWI). Panel members must disclose all relationships with industry regardless of relevance to the guideline topic (see below). When a potential conflict exists, the affected member must recuse during the formal consensus voting process. For more information on the CCS Guideline Development process, please visit [www.ccs.ca](http://www.ccs.ca).

Member	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit
<b>Primary Panel</b>			
Amer Jorhi	None	None	None
Paul Poirier	Abbott Vascular, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Servier, sanofi-aventis	Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Servier	None
Nate Moulson	None	None	None
Jimmy McKinney	None	None	None
Taryn Taylor	None	None	None
Francois Phillipon	Bayer, BMS Pfizer, Boehringer Ingelheim	Boston Scientific, Medtronic, St. Jude Medical, LivaNova	None
Paul Dorian	None	None	None
Andrew Pipe	Johnson & Johnson, Pfizer	Pfizer	None
Jack Goodman	None	None	None
Anne Fournier	AbbVie, Actelion	None	None
<b>Secondary Panel</b>			
Sanjay Sharma	None	None	None
Aaron Baggish			
Andrew Krahn	Medtronic	Medtronic	None

<b>Member</b>	<b>Consulting Fees/ Honoraria</b>	<b>Clinical Trials</b>	<b>Other Financial Benefit</b>